| Value | ₹0.49 Cr |
|---|
BSE filing, NSE: AGARWALEYE. Summary written from the filing by ALFA Finder's alert engine.
Dr. Agarwals Health Care Ltd: key numbers
- Share price
- ₹475.15
- Market cap
- ₹15,064 Cr
- Revenue (annual)
- ₹2,080 Cr
- Net profit (annual)
- ₹133.2 Cr
- P/E (TTM)
- 101.5×Sector 52.0×
- Promoter holding
- 32.33%-0.01% QoQ
- FII holding
- 49.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Agarwals Health Care Ltd
All →Dr. Agarwals Health Care Board Meeting Date
Dr. Agarwal's Health Care schedules a board meeting on November 5, 2026 to consider Q2 results. An earnings call follows at 6:30 PM IST that day.
Dr. Agarwals Health Care Merger & Restructuring Worth ₹711.2 Cr
Dr. Agarwals Health Care Limited has completed the merger of Dr. Agarwal's Eye Hospital Limited into itself for a total transaction value of ₹711.21 Crore.
- Value
- ₹711.2 Cr
Dr. Agarwals Health Care Employee Stock Options
Dr. Agarwal's Health Care Limited allotted 18,200 equity shares upon the exercise of vested ESOPs. The transaction is valued at approximately ₹0.24 Crore.
- Value
- ₹0.24 Cr
Dr. Agarwals Health Care Acquisition
The amalgamation scheme between Dr. Agarwal's Health Care and Dr. Agarwal's Eye Hospital is effective from November 01, 2026. The Record Date is November 18, 2026.
Dr. Agarwals Health Care Other Announcement
Dr. Agarwals Health Care Ltd has submitted its quarterly shareholding pattern statement for the quarter ended September 30, 2026, pursuant to SEBI Regulation 31(1)(b).
Dr. Agarwals Health Care Merger & Restructuring Worth ₹0.73 Cr
Dr. Agarwal's Health Care Ltd. completed the acquisition of its Nigeria-based step-down wholly owned subsidiary, previously announced on August 4, 2026, for ₹0.73 Crore.
- Value
- ₹0.73 Cr
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.